Literature DB >> 2305654

Nimodipine: evidence for clinically significant gastrointestinal side-effects.

E Hund1, A Aschoff, V Tronnier, J Hampl, S Kunze.   

Abstract

Nimodipine, now widely used for treatment and prevention of cerebrovascular spasm, is regarded as a safe drug. Despite a preferential action on cerebral vessels, there is clinical and experimental evidence of effects on systemic vascular and intestinal smooth muscle cells. Gastro-intestinal side-effects, however, have not been reported in clinical studies dealing with treatment of vasospasm following subarachnoid haemorrhage. We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of adynamic ileus, while being treated with intravenous nimodipine. The relationship between this complication and calcium antagonist therapy is discussed and therapeutic strategies are presented. We conclude that neurosurgeons and neurologists should be aware of calcium antagonist--related ileus in patients treated with nimodipine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2305654     DOI: 10.1007/bf01402190

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  30 in total

1.  Intrapulmonary shunting during deliberate hypotension with nifedipine, diltiazem and labetalol in dogs.

Authors:  P A Casthely; R Villanueva; L Rabinowitz; P Gandhi; B Litwak; P N Fyman
Journal:  Can Anaesth Soc J       Date:  1985-03

2.  Pseudoobstruction of the colon.

Authors:  B L Bachulis; P E Smith
Journal:  Am J Surg       Date:  1978-07       Impact factor: 2.565

Review 3.  Calcium-channel blockers and the gastrointestinal tract. American College of Gastroenterology's Committee on FDA related matters.

Authors:  M Traube; R W McCallum
Journal:  Am J Gastroenterol       Date:  1984-11       Impact factor: 10.864

Review 4.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

5.  Clinical experience with nimodipine in the prophylaxis of neurological deficits after subarachnoid hemorrhage.

Authors:  E Kazner; C Sprung; D Adelt; H P Ammerer; R Karnick; H Baumann; D K Böker; J A Grotenhuis; H Jaksche; A R Istaitih
Journal:  Neurochirurgia (Stuttg)       Date:  1985-05

6.  Clinical and manometric effects of nifedipine in patients with esophageal achalasia.

Authors:  M Bortolotti; G Labò
Journal:  Gastroenterology       Date:  1981-01       Impact factor: 22.682

7.  Regional selectivity of calcium blockers at intestinal level.

Authors:  C A Maggi; S Manzini; A Meli
Journal:  Arch Int Pharmacodyn Ther       Date:  1985-08

Review 8.  Ogilvie's syndrome (acute colonic pseudo-obstruction): review of the literature (October 1948 to March 1980) and report of four additional cases.

Authors:  G Nanni; A Garbini; P Luchetti; G Nanni; P Ronconi; M Castagneto
Journal:  Dis Colon Rectum       Date:  1982-03       Impact factor: 4.585

Review 9.  Calcium antagonism and calcium entry blockade.

Authors:  T Godfraind; R Miller; M Wibo
Journal:  Pharmacol Rev       Date:  1986-12       Impact factor: 25.468

10.  Pseudo-obstruction of the large bowel.

Authors:  N V Addison
Journal:  J R Soc Med       Date:  1983-04       Impact factor: 18.000

View more
  3 in total

Review 1.  A comparative review of the adverse effects of calcium antagonists.

Authors:  H T Dougall; J McLay
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

2.  Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage.

Authors:  F Porchet; R Chioléro; N de Tribolet
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

3.  Potential Association Between Acute Colonic Pseudo-Obstruction (Ogilvie Syndrome) and Oral Nimodipine: Report of Two Cases.

Authors:  Orlando De Jesus; Jose Sánchez Jiménez; Juan C Vicenty
Journal:  Cureus       Date:  2022-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.